Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Astrana Health Expands to 18 Markets, 1.5M Members

Astrana said it now operates in 18 markets nationwide, up from 17 markets in 2025, and has expanded to more than 20,000 providers and about 1.5 million members. The company’s footprint now includes nine markets in California, plus one each in Nevada, Arizona, Texas, Georgia, Florida, the DC/Maryland/Virginia area, Hawaii, Rhode Island and Connecticut.

The company highlighted several operating metrics tied to its care model. It said its model produced 67% fewer hospital admissions than benchmark, 14% shorter inpatient length of stay versus benchmark, and about 70% of prior authorizations were auto-approved instantly.

Astrana also described how quickly it has expanded geographically: one market in 2019, three in 2020, three in 2021, four in 2022, six in 2023, six in 2024, 17 in 2025 and 18 in 2026.

On the provider side, the company said it has more than 20,000 providers and cited example local networks in Southern California and Southern Nevada. In California’s San Gabriel Valley example, it pointed to 159 enterprise providers, 215 specialists, and 612 employed providers. In Southern Nevada, it cited 159 enterprise providers, 215 specialists and 612 employed providers as well.

The release also said Astrana’s operating model is built around a delegated structure that includes provider credentialing, network management, claims payment and payer contracting, with roughly 20 payer partners across its network. Following these announcements, the company's shares moved -2.35%, and are now trading at a price of $34.285. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS